.Back to listing
Sat, Mar 15
FDA wins high-profile support in consumer genetics kerfuffle
When the Food & Drug Administration last November ordered the Mountain View, Calif.-based firm 23andMe to stop marketing its health-related genetic test kit to consumers, the ensuing debate took on a “rage against the machine” tenor. Entrepreneurs, patients’ rights advocates and genetics geeks across the country argued that the plodding, risk-averse regulators of the FDA had neither the right nor the expertise to insert themselves between people wishing to own whatever mysteries their genes contained, and a company that promised to deliver such information. Now, however, a pair of respected experts in the dual fields of genetics and bioethics has weighed in — on the side of the FDA. Read more.